Skip to content

Study · Animal study (in vivo) · mouse · 2022

4 results

Melanocortin receptor agonists suppress experimental autoimmune uveitis.

Ng TF, Dawit K, Taylor AW

Experimental eye research20 Feb 2022Cited by 17 (Europe PMC)

PMID35196505 (opens in a new tab)PMCIDPMC9050930 (opens in a new tab)DOI10.1016/j.exer.2022.108986 (opens in a new tab)PepBankPUB-35196505
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with experimental autoimmune uveitis, MTII did not suppress EAU.

    In plain wordsIn mice with eye inflammation, MTII did not reduce the disease.

    Peptide
    Melanotan II
    Outcome
    No significant changeSuppression of experimental autoimmune uveitis
    Study

    mousen: not reported in source

    Mice with experimental autoimmune uveitis (EAU)
    Outcome group
    Inflammation markers · Eye
    Studied dose
    50 μg, injected twice 1 day apartAs given in this study (mouse).

    Source sentences

    Summary
    In EAU mice treated with PL5000, MTII, or PG901, there was no suppression of EAU
    1 context sentence
    Summary · context
    At the chronic stage of EAU the mice were injected twice 1 day apart with 50 μg of α-MSH or an α-MSH-analog.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with experimental autoimmune uveitis, MTII treatment was followed by significant loss of whole retina and outer-nuclear layer thickness.

    In plain wordsIn mice with eye inflammation, MTII did not protect the retina, which lost thickness.

    Peptide
    Melanotan II
    Outcome
    DecreaseRetinal structure (whole retina and outer-nuclear layer thickness)
    Study

    mousen: not reported in source

    Mice with experimental autoimmune uveitis (EAU)
    Outcome group
    Inflammation markers · Eye
    Studied dose
    50 μg, injected twice 1 day apartAs given in this study (mouse).

    Source sentences

    Summary
    In EAU mice treated with PL5000, MTII, or PG901, there was no suppression of EAU with a significant loss in whole retina and outer-nuclear layer thickness.
    1 context sentence
    Summary · context
    At the chronic stage of EAU the mice were injected twice 1 day apart with 50 μg of α-MSH or an α-MSH-analog.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In mice with experimental autoimmune uveitis, MT-II treatment did not suppress IL-17 production by retinal-antigen stimulated spleen T cells.

    In plain wordsIn mice with eye inflammation, MT-II did not lower IL-17, an inflammation signal, in spleen immune cells.

    Peptide
    Melanotan II
    Outcome
    No significant changeIL-17 production by retinal-antigen stimulated spleen T cells
    Study

    mousen: not reported in source

    Mice with experimental autoimmune uveitis (EAU)
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    50 μg, injected twice 1 day apartAs given in this study (mouse).

    Source sentences

    Summary
    There was significant suppression of IL-17 with induction of IL-10 by retinal-antigen stimulated spleen T cells from EAU mice treated with α-MSH, PL8331, PL8177, or PL5000, but not from EAU mice treated with MT-II, or PG901.
    1 context sentence
    Summary · context
    At the chronic stage of EAU the mice were injected twice 1 day apart with 50 μg of α-MSH or an α-MSH-analog.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In mice with experimental autoimmune uveitis, MT-II treatment did not induce IL-10 production by retinal-antigen stimulated spleen T cells.

    In plain wordsIn mice with eye inflammation, MT-II did not raise IL-10, an anti-inflammatory signal, in spleen immune cells.

    Peptide
    Melanotan II
    Outcome
    No significant changeIL-10 production by retinal-antigen stimulated spleen T cells
    Study

    mousen: not reported in source

    Mice with experimental autoimmune uveitis (EAU)
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    50 μg, injected twice 1 day apartAs given in this study (mouse).

    Source sentences

    Summary
    There was significant suppression of IL-17 with induction of IL-10 by retinal-antigen stimulated spleen T cells from EAU mice treated with α-MSH, PL8331, PL8177, or PL5000, but not from EAU mice treated with MT-II, or PG901.
    1 context sentence
    Summary · context
    At the chronic stage of EAU the mice were injected twice 1 day apart with 50 μg of α-MSH or an α-MSH-analog.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.